Caihong Feng Selected Research

2- (dibenzo(b,d)furan- 2- yl)- 7- phenyl- 1- (3- (piperidin- 1- yl)propyl)- 1H- imidazo(4,5- g)quinoxalin- 6(5H)- one

1/2013

CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Caihong Feng Research Topics

Disease

1	Neoplasms (Cancer) 01/2017
1	Conversion Disorder (Astasia Abasia) 07/2015
1	Prostatic Neoplasms (Prostate Cancer) 01/2013
1	Neoplasm Metastasis (Metastasis) 01/2013

Drug/Important Bio-Agent (IBA)

1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017
1	cupric sulfide (CuS)IBA 07/2015
1	2- (dibenzo(b,d)furan- 2- yl)- 7- phenyl- 1- (3- (piperidin- 1- yl)propyl)- 1H- imidazo(4,5- g)quinoxalin- 6(5H)- oneIBA 01/2013
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2013

Therapy/Procedure

1	Precision Medicine 01/2017